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Abstract
Background: Primary hypoadrenocorticism (or Addison’s disease, AD) is an autoimmune disease that results in
destruction of the adrenal cortex and consequent adrenal insufficiency. The disease has been described in purebred
and mixed breed dogs, although some breeds, including the Bearded Collie, are at increased risk for AD. Candidate
gene approaches have yielded few associations that appear to be breed-specific. A single other genome-wide
association study reported no significant regions of association for AD in Standard Poodles. The present study
aimed to identify genomic regions of association for canine AD in Bearded Collies.
Results: Our study consists of the first genome-wide association analysis to identify a genome-wide significant
region of association with canine AD (CFA18). Peaks of suggestive association were also noted on chromosomes 11,
16 and 29. Logistic regression analysis supported an additive effect of risk genotypes at these smaller effect loci on
the probability of disease associated with carrying a risk genotype on CFA18. Potential candidate genes involved in
adrenal steroidogenesis, regulation of immune responses and/or inflammation were identified within the associated
regions of chromosomes 11 and 16. The gene-poor regions of chromosomes 18 and 29 may, however, harbor
regulatory sequences that can modulate gene expression and contribute to disease susceptibility.
Conclusion: Our findings support the polygenic and complex nature of canine AD and identified a strongly
associated locus on CFA18 that, when combined with three other smaller effect loci, was predictive of disease. The
results offer progress in the identification of susceptibility loci for canine AD in the Bearded Collie. Further studies
are needed to confirm association with the suggested candidate genes and identify actual causative mutations
involved with AD susceptibility in this breed.
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Background
Primary hypoadrenocorticism or Addison’s disease (AD;
OMIA 000520–9615) results from immune-mediated de-
struction of the adrenal cortex, leading to a life-threatening
clinical condition characterized by inadequate secretion of
adrenocortical hormones. The disease has been reported in
many purebred and mixed breed dogs [1, 2], with prevalence
up to 0.5% in the overall canine population [3–7]. However,
multiple breeds appear to be predisposed to AD [2, 8–10],
including Bearded Collies, Portuguese Water Dogs (PWD),
Standard Poodles, West Highland White Terriers, Leonber-
gers, Wheaten Terriers, and Nova Scotia Duck Tolling
Retrievers (NSDTRs) [2, 5, 7, 11–13], and disease prevalence
in these breeds can be as high as 9% [4, 14–16].
Similar to humans, studies on canine AD have suggested
a female predisposition [7, 12], although males and females
appear to be equally affected in Bearded Collies [16], PWD
[1] and Standard Poodles [15]. Average age of onset is 4
years for all dog breeds [2, 7, 11], and most dogs are diag-
nosed between 2 and 7 years of age [17]. An exception is
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the NSDTR, for which average age of onset is 2 to 3 years
[7, 13]. However, recent findings suggest that the NSDTRs
are affected by two types of AD: a juvenile type often seen
as part of a multisystemic autoimmune syndrome and diag-
nosed at a much earlier age, and an adult-onset AD that
corresponds to the AD seen in other dog breeds [18].
Disease pathogenesis is similar in dogs and humans [2,
8–10, 19], with lymphocytic infiltration of adrenal tissue,
autoantibody production against adrenocortical antigens
and impaired steroidogenesis characterizing AD in both
species [19–22]. Although autoantibodies against adrenal
antigens are observed in > 80% of human AD patients
[21], providing important diagnostic and predictive infor-
mation, in dogs, autoantibodies have only been identified
in 24% of AD patients [23], indicating limited usefulness
as a diagnostic tool for canine AD.
Genetic predisposition for disease is evident in both dogs
and humans [1, 8, 15, 16, 19, 24, 25], and genes implicated
in increased susceptibility to human AD include the major
histocompatibility complex (MHC) class II genes (haplo-
types DR3-DQ2 and DR4-DQ8), cytotoxic T-lymphocyte-
associated protein 4 (CTLA4), protein tyrosine-phosphatase
non-receptor type 22 (PTPN22), MHC class II transactiva-
tor (CIITA) [19, 24, 26], and the autoimmune regulator
(AIRE) gene, which causes an autoimmune polyglandular
syndrome that includes AD [24]. Although canine pedigree
studies have indicated a recessive autosomal mode of inher-
itance for AD in the Standard Poodle and PWD [1, 15], a
recent genome-wide association study (GWAS) on Stand-
ard Poodles failed to demonstrate significant associations
with AD, suggesting a more complex mode of inheritance
[27]. Candidate gene approaches have implicated many of
the same genes identified in human AD with increased sus-
ceptibility to canine AD: CTLA4 in the PWD, Cocker Span-
iel and Springer Spaniel [10, 14, 28]; PTPN22 in the Cocker
Spaniel [10]; and the canine MHC (or dog leukocyte anti-
gen, DLA) class II genes in the NSDTR, Bearded Collie and
Standard Poodle [29–31]. Particular single nucleotide poly-
morphisms (SNPs) in CTLA4 and collagen type IV alpha 4
chain (COL4A4) have been associated with AD in the
Springer Spaniel, whereas SNPs in oxysterol binding pro-
tein like 9 (OSBPL9) and PTPN22 were implicated in the
Cocker Spaniel, and SNPs in syntaxin-binding protein 5
(STXBP5) in the Labrador Retriever. Two different genes
(the vitamin D binding protein group-specific component
(GC) and the SP110 nuclear body protein (SP110)) were in-
vestigated for association with AD in Bearded Collies,
though no statistical significance was seen after correcting
for multiple testing [32].
Taken together, these studies indicate the existence of
genetic commonalities and breed-specificity in canine AD,
underscoring the need for additional research to elucidate
the genetic basis of this disease in dogs. A 2019 health sur-
vey conducted by the Bearded Collie Foundation for Health
showed a relatively high prevalence of autoimmune
conditions in the breed (11.1% based on 3072 Bearded
Collies included in the survey). Of these, 3.1% had been
diagnosed with primary hypoadrenocorticism [33].
Therefore, the present study aimed to identify genetic
loci associated with AD in Bearded Collies by interro-
gating the genome. Given the likely polygenic nature of
canine AD, we hypothesized that more than one gen-
omic region would be associated with disease develop-
ment and that those associated regions would harbor
genes related to immune function and regulation.
Results
Genome-wide association study
PLINK and GEMMA analyses on unrelated dogs identi-
fied a peak on canine chromosome (CFA) 18 (Fig. 1a
and b), with a single SNP (BICF2P1230367 at 28,207,
384 bp) reaching genome-wide significance.
To complement the findings in the GWA analyses, 37
additional minimally related dogs (3 male and 11 female
AD cases, 11 male and 12 female controls) were genotyped
for the top CFA18 SNP and the odds ratios (OR) calculated
(Table 1; Additional Table 1); the total number of males
and females analyzed across the cases and controls did not
significantly differ (p > 0.05). Two genotypes were associ-
ated with increased risk for AD on CFA18; dogs homozy-
gous for the alternate genotype (AA) or those with
a heterozygous (AG) genotype were at higher risk for dis-
ease than those carrying a homozygous CanFam3.1 refer-
ence (GG) genotype (OR = 5.8, 95% CI = 2.62–12.92, p =
0.00001, and OR= 4.7, 95% CI = 1.53–14.70, p = 0.00742,
respectively).
Recognizing the complex nature of AD, we anticipated
smaller effect loci contributing to AD expression, though
perhaps not reaching genome-wide significance. A sug-
gestive threshold was therefore set at p ≤ 0.00005 [34,
35]. Peaks of suggestive association were noted on chro-
mosomes 11, 16 and 29. The GEMMA analyses yielded
similar observations after accounting for the genetic
structure of the sample (Fig. 1c). Specifically, the same
top SNPs were observed in both PLINK and GEMMA
analyses, although the SNP on CFA11 did not quite
reach the suggestive threshold in the latter. Odds ratios
were also calculated for these suggestive SNPs in all 140
dogs, which included the additional 37 dogs mentioned
above (Table 2).
A homozygous alternate genotype was associated with
increased risk for AD at both CFA16 (i.e. GG) and
CFA29 (i.e. CC) SNPs, both contributing similar risk for
disease (OR = 4.0, 95% CI = 1.87–8.70, p = 0.00038; and
OR = 4.2, 95% CI = 1.95–8.88, p = 0.00019, respectively).
The highest OR obtained was associated with the homo-
zygous alternate genotype on CFA11 (GG; OR = 21.0,
95% CI = 2.63–167.99, p = 0.00015). However, that risk
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Fig. 1 Manhattan Plots. Chi-square based allelic association (A) and association testing after 100,000 max(T) permutations (B) in PLINK for 103
unrelated Bearded Collies (41 cases, 62 healthy controls; λGC = 1.2280). (C) Association testing using GEMMA’s univariate linear mixed model
approach to account for population substructure of the same dataset (λGC = 1.0328). The blue and red lines indicate suggestive (p < 0.00005;
−log10[p-value]≥ 4.3) and Bonferroni-adjusted genome-wide significance threshold (−log10[p-value] ≥ 5.75), respectively
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genotype was observed in a single control dog and was
only present in 20% of cases. Interestingly, all dogs car-
rying a risk genotype on CFA11 (GG) also carried the
risk genotype on CFA16 (GG).
When the significant SNP on CFA18 and the suggestive
SNPs on chromosomes 11, 16 and 29 were considered, as
the number of risk genotypes increased, so did the risk for
AD. That is, within these 140 dogs, dogs carrying risk ge-
notypes at any one or more of these four evaluated SNPs
were at greater risk for AD than dogs carrying only non-
risk genotypes at all four SNPs (Fig. 2). Specifically, dogs
carrying one or two risk genotypes were at greater risk for
AD than dogs having none (OR = 17.0, 95% CI = 2.21–
130.70, p = 0.00028), and dogs carrying risk genotypes at
three or four of the SNPs were at greater risk for AD than
those carrying one or two risk genotypes (OR = 32.9, 95%
CI = 4.23–256.68, p = 9.03 × 10− 7).
To further investigate the observation that risk for AD
increased with the number of risk genotypes a dog car-
ried, logistic regression analysis was used to assess the
genotypic contribution of each of the four SNPs of inter-
est (the genome-wide significant CFA18 SNP and the
suggestive SNPs on chromosomes 11, 16 and 29) on the
probability of AD. Specifically, the analysis addressed the
question of whether a multi-SNP model was better than
the CFA18 single-SNP model in predicting the probabil-
ity that a Bearded Collie would be affected by AD. Sep-
arate 2-SNP, 3-SNP and 4-SNP models were developed
using the genotypes of the 55 Addisonian and 85 healthy
control Bearded Collies. Lower leave-one-out
information criterion (looic) values were noted for the
multi-SNP models compared to the single-SNP ones.
The lowest looic value was associated with the 4-SNP
model, indicating that this model presented the best and
most parsimonious fit for AD prediction in the study
Table 1 Odds Ratio for the CFA18 SNP Significantly Associated
with Addison’s Disease






OR (95% CI)* p-value
A A 7 9 2.2 (0.76–6.25) 0.17613
G A 19 30 4.2 (2.00–8.70) 0.00013
G G 59 16 0.2 (0.09–0.38) 4.72 × 10−6
A A 7 9
vs 4.7 (1.53–14.70) 0.00742
G G 59 16
G A 19 30
vs 5.8 (2.62–12.92) 0.00001
G G 59 16
Odds ratio (OR) for the CFA18 single nucleotide polymorphism (SNP)
associated with Addison’s disease (AD) in 140 Bearded Collies (55 AD cases, 85
healthy controls). Bolded values were statistically significant at p < 0.05.
*CI Confidence interval, #SNP location is based on the CanFam3.1 reference
genome






OR (95% CI)* p-value
CFA11 SNP (BICF2G630307993–71,446,591; CanFam3.1 reference allele A)#
G G 1 11 21.0 (2.63–167.99) 0.00015
G A 29 23 1.4 (0.69–2.79) 0.37576
A A 55 21 0.3 (0.17–0.68) 0.00303
G G 1 11
vs 28.8 (3.50–237.15) 0.00004
A A 55 21
G A 29 23
vs 2.1 (0.99–4.37) 0.06010
A A 55 21
CFA16 SNP (BICF2G630109748–27,126,780; CanFam3.1 reference allele C)
G G 40 43 4.0 (1.87–8.70) 0.00038
C G 35 12 0.4 (0.18–0.86) 0.02728
C C 10 0 NA§ 0.01403
G G 40 43
vs NA 0.00151
C C 10 0
C G 35 12
vs NA 0.09974
C C 10 0
CFA29 SNP (BICF2P977298–30,615,809; CanFam3.1 reference allele A)
C C 16 27 4.2 (1.95–8.88) 0.00019
C A 47 20 0.5 (0.23–0.93) 0.03760
A A 22 8 0.5 (0.20–1.19) 0.14087
C C 16 27
vs 4.6 (1.68–12.85) 0.00397
A A 22 8
C A 47 20
vs 1.2 (0.45–3.07) 0.81259
A A 22 8
Odds ratio (OR) for the top suggestive single nucleotide polymorphisms (SNPs)
on chromosomes 11, 16, and 29 in 140 Bearded Collies (55 Addison’s disease
(AD) cases, 85 healthy controls). Bolded values were statistically significant at
p < 0.05.
§NA not enough data points collected for OR calculation,*CI Confidence
interval, #SNP locations are based on the CanFam3.1 reference genome
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population (Additional Table 2). Based on the known ge-
notypes and associated phenotypes, logistic regression
calculated the probability of disease associated with
every possible genotypic combination, even those that
were not included in the data set (Additional Fig. 1), but
only those associated with the highest risk genotypes are
presented in the subsequent tables.
Taking the probability of disease associated with a
CFA18 risk genotype as baseline, the addition of one
other risk genotype at any of the three suggestive SNPs,
in a 2-SNP interaction model, tended to increase the
probability for AD, although a significant increase over
the CFA18 SNP alone was only noted with the addition
of a risk genotype on CFA11 (Table 3).
In contrast with the 2-SNP model, when considering a
3-SNP model, the addition of a risk genotype at any two
suggestive SNPs also tended to increase the probability of
AD in dogs carrying a risk genotype on CFA18, with
significant increases noted for almost all possible 3-SNP
risk genotype combinations. For the 4-SNP model, the
addition of all four SNPs did not substantively increase
the estimate of AD probability over the 3-SNP model
likely reflecting that dogs that had a risk genotype on
CFA11 also had the risk genotype on CFA16. Conversely,
the probability of disease associated with carrying only
non-risk genotypes at all four SNPs was extremely low for
almost all possible 4-SNP combinations (Table 4).
Haplotype analysis
To refine the regions of association for candidate gene ex-
ploration, haplotype analysis was done for the four chromo-
somes. Eighteen haplotype blocks were significantly
associated with AD (seven on CFA11, six on CFA16 and
five on CFA18; permuted p-value< 0.05; Additional Table
3), and seven of them overlapped protein-coding genes.
The location and distribution of the seven haplotype blocks
on CFA11 indicate the existence of two associated regions
separated by less than 2Mb on CFA11 (Fig. 3a): one at the
Fig. 2 Number of Risk Genotypes in Case and Control Bearded Collies.
Number of SNPs containing risk genotypes for Addison’s disease (AD)
in 140 Bearded Collies (55 AD cases, 85 controls)
Table 3 Probability of Disease Based on Number of Risk Genotypes
Number of SNPs in model CFA18 CFA11 CFA16 CFA29 Controls (N = 85) AD
(N = 55)
Probability of disease 95% CI*
Single SNP A A – – – 7 9 0.540 0.328–0.747
Single SNP A G – – – 19 30 0.613 0.479–0.744
2-SNP A A G G – – 1 1 0.877 0.637–0.988
2-SNP A G G G – – 0 7 0.925 0.770–0.991
2-SNP A A – G G – 4 8 0.641 0.407–0.834
2-SNP A G – G G – 11 22 0.697 0.552–0.824
2-SNP A A – – C C 1 5 0.757 0.524–0.915
2-SNP A G – – C C 2 14 0.822 0.677–0.924
3-SNP A A G G G G – 1 1 0.885 0.653–0.988
3-SNP A G G G G G – 0 7 0.926 0.779–0.991
3-SNP A A G G – C C 0 1 0.950 0.803–0.996
3-SNP A G G G – C C 0 4 0.973 0.902–0.998
3-SNP A A – G G C C 0 5 0.833 0.619–0.952
3-SNP A G – G G C C 0 11 0.872 0.750–0.953
4-SNP A A G G G G C C 0 1 0.956 0.821–0.997
4-SNP A G G G G G C C 0 4 0.974 0.901–0.998
Probability of disease associated with carrying one, two or three risk genotypes at the suggestive single nucleotide polymorphisms (SNPs) on chromosomes 11, 16
and/or 29 in addition to a CFA18 risk genotypes for Addison’s disease (AD) in 140 Bearded Collies (55 AD cases, 85 healthy controls). Comparisons provided are
for genotypes associated with significant risk as detailed in Table 2. Bolded values indicate significant increase in the probability of disease associated with the
additive effect of risk genotypes across 2 SNPs, 3 SNPs and all 4 SNPs of interest.
* CI Confidence interval
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69Mb range and the other at 71Mb. Moreover, one of the
haplotype blocks on CFA11 overlapped with a protein-
coding gene of utmost importance to the immune system:
the toll-like receptor 4 (TLR4) gene.
Similar to CFA11, five haplotype blocks on CFA16
clustered around the 27Mb range (Fig. 3b), coinciding
with the location of the top GWAS SNP (located within
haplotype block 4), whereas a sixth haplotype block was
located approximately 2Mb upstream of that region.
Moreover, four of the haplotype blocks overlapped
protein-coding genes: zinc finger matrin-type 4
(ZMAT4), fibroblast growth factor receptor 1 (FGFR1),
leucine zipper and EF-hand containing transmembrane
protein 2 (LETM2), eukaryotic translation initiation fac-
tor 4E binding protein 1 (EIF4EBP1), adrenoreceptor
beta 3 (ADRB3), glutamic-oxaloacetic transaminase 1
like 1 (GOT1L1), RAB11 family interacting protein 1
(RAB11FIP1) and BRF2 RNA polymerase III transcrip-
tion initiation factor subunit (BRF2).
Unlike with chromosomes 11 and 16, none of the
haplotype blocks on CFA18 contained the top GWAS
SNP (Fig. 3c), which is located about half-way between
haplotype blocks 4 and 5. Four of the haplotype blocks
were clustered around the 27Mb range, spanning a total
of 1.2Mb in a region containing various RNA genes and
few protein-coding genes. The fifth block was located
almost 11Mb upstream of that region and overlapped
with two protein-coding genes: reelin (RELN) and solute
carrier family 26 member 5 (SLC26A5). No haplotype
blocks were associated with AD on CFA29 (Fig. 3d).
Discussion
The present study reports the first genome-wide associ-
ation analysis to identify a statistically significant region
of association with canine AD. Three suggestive smaller
effect loci were also identified and shown to contribute
to increased risk for AD in Bearded Collies. Previous
studies focused on candidate gene approaches yielded
few associations, most of which appear to be breed spe-
cific [2, 9, 10, 28, 32, 36]. Similar to human AD [24],
MHC (or DLA) class II genes have shown the most con-
sistent associations with canine AD to date, even though
different DLA class II haplotypes have been associated
with increased risk for the disease in different breeds [9,
29–31]. However, DLA class II haplotypes fail to com-
pletely explain AD development in both dogs and
humans, and only 37.7% of Bearded Collies with AD
possess the breed’s identified DLA class II risk haplotype
for the disease [29]. This may explain the lack of associ-
ation with the DLA class II locus on CFA12 in the
present study and underscores the importance of identi-
fying additional loci contributing to AD risk.
Although sample size was a limitation of this study,
a genome-wide significant region of association was
identified on CFA18, revealing two risk genotypes for
the top CFA18 SNP (AA and AG). Given the com-
plex nature of canine AD, a single major locus associ-
ated with disease risk was not expected. Instead,
complex traits are likely governed by multiple loci of
smaller effects in addition to environmental factors,
and SNPs representing these smaller effect genomic
regions are not likely to reach genome-wide signifi-
cance [35]. Peaks reaching the suggestive threshold
for disease association were identified on chromo-
somes 11, 16, and 29, and a homozygous alternate
genotype at the top SNP of each chromosome was as-
sociated with increased risk for AD.
Grouping of the dogs based on the number of risk
genotypes they carried at all four SNPs indicated that, as
the number of risk genotypes increased, so did the risk for
AD. Logistic regression analysis further supported a con-
tribution of additional risk genotypes at these smaller
Table 4 Probability of Disease for Dogs Carrying only Non-risk Genotypes
SNP Genotypes Number of Dogs with Genotype Combination in Dataset Probability of Disease
CFA18 CFA11 CFA16 CFA29 Controls (N = 85) AD cases (N = 55) Probability 95% CI*
G G A A C C A A 0 0 0.024 0.002–0.087 a
G G A A C C C A 3 0 0.021 0.002–0.079
G G A A C G A A 3 0 0.067 0.016–0.170
G G A A C G C A 10 0 0.056 0.014–0.131
G G G A C C A A 0 0 0.061 0.006–0.209 a
G G G A C C C A 2 0 0.052 0.005–0.190
G G G A C G A A 3 0 0.157 0.044–0.355
G G G A C G C A 7 1 0.134 0.041–0.558
The table shows the probability of Addison's disease (AD) for dogs carrying only non-risk genotypes at all four single nucleotide polymorphisms (SNPs) of interest
*CI Confidence interval
aalthough none of the dogs in the dataset carried these genotypic combinations, logistic regression model allowed for the estimation of the probability of disease
given the known genotypes and phenotypes.
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Fig. 3 Location of Haplotype Blocks Associated with Addison’s Disease in Bearded Collies. Diagram showing the top GWAS SNPs and location of
haplotype blocks on (A) CFA11, (B) CFA16, (C) CFA18 and (D) CFA29. No haplotype blocks were associated with Addison’s disease on CFA29. Top
GWAS SNPs in each chromosome are listed in red
Gershony et al. BMC Genomics          (2020) 21:833 Page 7 of 13
effect loci (on chromosomes 11, 16 and 29) to the prob-
ability of disease associated with a risk genotype on
CFA18, with a 4-SNP model presenting the best fit for
predicting the probability of AD in the study population
although a 3-SNP model showed similar performance and
captured a greater number of AD cases. Notably, despite
presenting the best fit, only ~ 10% of AD dogs carried risk
genotypes at all 4 SNPs. While one might anticipate a
greater number of AD cases to be captured by such a
comprehensive model, especially when the study cohort
consisted of a single dog breed expected to be genetically
similar, complex inherited diseases such as AD may not
require the presence of every single risk locus for disease
development.
It should also be mentioned that the small sample size
meant that many possible genotypic combinations were
not represented in the dataset. Nevertheless, logistic re-
gression analysis still allows for prediction of disease risk
for all plausible genotype combinations, recognizing that
the predictions in these “empty cells” is not very precise
and the confidence intervals surrounding the probability
estimates will be large. Based upon our assessment of
genotype effects at these four chromosomes, there were
genotype combinations that could be considered high
risk for AD and others showing strong evidence of being
associated with dogs not afflicted with AD, as shown in
Additional Fig. 1. However, the amount of risk conferred
by each SNP, or combinations of SNPs, remains unclear.
The highest OR was associated with a homozygous al-
ternate genotype for the top CFA11 SNP, and all 2-SNP,
3-SNP and 4-SNP genotypic combinations showing the
highest probability of disease carried the CFA11 risk
genotype. However, this genotype was only seen in 20%
(11/55) of cases, which might suggest heterogeneity of
our case group despite our strict inclusion criteria. Given
that all dogs carrying the risk genotype on CFA11 also
carried a risk genotype on CFA16, it is more likely that
the very high risk for AD seen in dogs carrying the
CFA11 risk genotype is due to an additive effect of the
two risk genotypes. This fact may also have confounded
the 3-SNP and 4-SNP models, and may be why no sig-
nificant differences were seen between the probability of
disease in dogs carrying three or four risk genotypes.
The genome-wide significant SNP identified in our
study lands in a gene-poor region of CFA18. The closest
protein-coding gene is LRRC4C (leucine rich repeat con-
taining 4C, also known as netrin-G1 ligand, NGL-1), lo-
cated approximately 600 kb downstream of the SNP and
involved in thalamocortical axon guidance during em-
bryonic development [37]. No other protein-coding
genes were identified within 1Mb upstream or down-
stream of the SNP. Based upon the literature, LRRC4C
has no connection to immune function, inflammation,
or adrenal development. However, long noncoding RNA
(lncRNA) genes can be found approximately 500Kb up-
stream and downstream of the associated SNP. Long
noncoding RNAs have limited or no protein-coding cap-
acity, but can regulate various biological processes, in-
cluding immune cell development and function. These
molecules can also act as transcriptional regulators of
neighboring genes, and recent studies have implicated
lncRNAs in autoimmune diseases such as systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA) [38].
Gene-poor regions of the genome have also been shown
to harbor regulatory sequences that can bind transcrip-
tion factors and regulate gene expression. In fact, more
than half of the GWAS variants associated with human
autoimmune diseases fall in enhancer elements, attribut-
ing much of the genetic risk for autoimmune conditions
to the modulation of gene expression [39]. Whereas the
mapping of regulatory elements to the canine genome is
not yet available, research teams affiliated with The Dog
Genome Annotation Project (DoGA) have been working
to generate such functional annotation to facilitate the
study of canine diseases.
Haplotype analysis on CFA18 indicated a second region
of association approximately 12Mb upstream of the
genome-wide significant SNP. The haplotype block identi-
fied in this region overlaps two genes RELN and SLC26A5.
However, based on the literature, neither appear to be po-
tential candidate genes for canine AD. SLC26A5 encodes
an anion transporter molecule responsible for electromoti-
lity in mammalian auditory sensory hair cells [40], and
mutations in the human gene have been associated with
hearing loss (autosomal recessive deafness; OMIM
604943). RELN plays a critical role in brain formation, and
mice with Reln deficiency (i.e. reeler mice) present with
malformations of the cerebral cortex [41]. Though immune
abnormalities have been reported in reeler mice, they were
not compatible with autoimmune diseases and character-
ized by reduced cytokine production, T cell proliferation
and B cell responses [42].
The top CFA11 SNP was located within a lncRNA gene
adjacent to TLR4. As mentioned above, lncRNAs may be
involved in autoimmunity through the regulation of
neighboring genes [38]. Moreover, five haplotype blocks
were identified in that region, one of which overlapped
with TLR4. TLR4 is a membrane-bound pattern recogni-
tion receptor expressed in macrophages, dendritic cells
and T lymphocytes, and binding of this receptor results in
the activation of signaling pathways that lead to the pro-
duction of pro-inflammatory cytokines, chemokines and
costimulatory molecules that activate the adaptive im-
mune response [43]. Dysregulation of TLR4 signaling may
result in overt activation of proinflammatory signals, thus
increasing the risk for autoreactive lymphocyte activation.
Autoimmune diseases that have been associated with
TLR4 include RA, SLE and type 1 diabetes [44].
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Two haplotype blocks associated with AD were also
identified approximately 1.5 Mb upstream of the top
CFA11 GWAS SNP. Two immune genes can be found
within 50Kb upstream of the haplotype blocks: TNF
superfamily member 15 (TNFSF15) and TNF superfam-
ily member 8 (TNFSF8). TNFSF15 is a member of the
tumor necrosis factor family of ligands that can influ-
ence the proliferation, activation and differentiation of
immune cells, including T cells. TNFSF15 expression
can be induced in monocytes, macrophages and den-
dritic cells through TLR signaling, for instance, and in T
lymphocytes in response to T-cell receptor (TCR) bind-
ing under inflammatory conditions [45]. Polymorphisms
in this gene have been associated with several auto-
immune diseases, such as RA, inflammatory bowel dis-
ease, Crohn’s disease [46], SLE, and Grave’s disease – a
polygenic organ-specific autoimmune thyroid condition
[47]. Similarly, TNFSF8 (also known as CD30 ligand)
also plays a role in modulating T cell responses, where
binding of these ligands on T lymphocytes results in
augmented cell proliferation and cytokine production
[48]. Despite its recognized potential role in autoimmun-
ity, to the best of our knowledge, no associations be-
tween polymorphisms in TNFSF8 have been reported
for any specific autoimmune disorder.
The top SNP on CFA16 was intergenic and located in a
gene-rich region of the chromosome. Similar to chromo-
somes 11 and 18, haplotype blocks associated with AD
suggested two regions of association approximately 1Mb
apart on CFA16. Four of the six haplotype blocks over-
lapped with protein-coding genes: ZMAT4, FGFR1,
LETM2, EIF4EBP1, GOT1L1, RAB11FIP1, BRF2 and beta-
3 adrenergic receptor (ADRB3). However, literature review
showed no evidence of their direct connection to immune
function or adrenal development, making them unlikely
candidates for susceptibility to canine AD. While
EIF4EBP1 and FGFR1 are involved in the PI3K-Akt signal-
ing pathway, which does play a role in regulating immune
cell effector functions through various mechanisms [49], a
more likely candidate gene for AD susceptibility would be
indoleamine 2,3-dioxygenase 2 (IDO2), one of two neigh-
boring genes involved in tryptophan catabolism and
modulation of immune responses. The better character-
ized gene, IDO1, is known to modulate the immune sys-
tem by altering regulatory T cell populations. Although
IDO2 is less efficient at catabolizing tryptophan, it is
expressed in antigen presenting cells and has been re-
cently implicated in driving B-cell mediated and T cell-
dependent autoimmune responses [50, 51].
It should also be noted that a gene involved in ste-
roidogenesis can be found 200Kb downstream of the
top CFA16 SNP: the steroidogenic acute regulatory
protein (STAR) gene. This gene encodes a mitochon-
drial transporter protein that transfers cholesterol
from the outer to the inner mitochondrial membrane
where steroidogenesis is initiated. Various inactivating
mutations in STAR result in lipoid congenital adrenal
hyperplasia, a severe (and usually fatal) condition that
manifests within the first weeks to months of life. Se-
vere STAR deficiency also causes failed testosterone
production in utero resulting in males being born
with female genitalia [52]. While inactivating muta-
tions in STAR are extremely unlikely to be involved
in canine AD, normal steroidogenesis in the adrenal
glands is thought to suppress antigen presentation
within the adrenal cortex [19]. It is, therefore, pos-
sible that mutations in STAR causing even a mild
reduction in steroidogenesis could promote a break-
down of tolerance to adrenocortical antigens, thus fa-
cilitating the onset of autoimmunity.
No haplotype blocks associated with AD were identi-
fied on CFA29. The two top SNPs on that chromosome
marked a 1Mb region of the chromosome that con-
tained three protein-coding genes, two of which were
uncharacterized. No potential candidate genes for canine
AD were identified in the associated region of this
chromosome.
Susceptibility to complex human autoimmune dis-
eases, including AD, is commonly associated with an ac-
cumulation of small effect variants in multiple immune-
related genes that are usually insufficient to cause dis-
ease on their own [53]. Moreover, complex traits such as
AD are influenced by environmental factors that may act
as triggers for disease expression in some but not all car-
riers of risk genotypes. Though based upon a relatively
small sample size, our findings are consistent with these
observations, and suggest a combination of risk geno-
types in different genomic loci contributing to AD devel-
opment in Bearded Collies. While a larger sample size
may help further elucidate the contributions of each as-
sociated region, it is unlikely that we would be able to
expand the sample to any great degree given the rela-
tively small actual and effective population size of
Bearded Collies [54]. Incomplete penetrance and poten-
tial genetic heterogeneity of canine AD may also limit
our ability to determine the amount of risk each region
confers. Low prevalence, complex nature, incomplete
penetrance and potential heterogeneity makes it challen-
ging to investigate the genetic basis of human AD [19],
and similar challenges exist with canine AD, even within
predisposed dog breeds. Nonetheless, our study offers
progress in the identification of susceptibility loci for ca-
nine AD in Bearded Collies.
Conclusions
Despite the small sample size, the present study identi-
fied a genome-wide significant region of association with
canine AD on CFA18, in addition to suggestive regions
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of association on chromosomes 11, 16 and 29. Logistic
regression supported an additive contribution of risk ge-
notypes at each of the associated loci to the probability
of developing AD in Bearded Collies. Associated loci
overlap with potential candidate genes for AD suscepti-
bility that have roles regulating adrenal steroidogenesis,
immune responses and/or inflammation. These findings
offer progress in the identification of susceptibility loci
for canine AD Bearded Collies, though further studies
are needed to confirm association of the identified can-
didate genes and determine actual causative mutations
involved with AD susceptibility in this breed.
Methods
Samples
Blood or buccal swab samples from privately owned Ad-
disonian and healthy Bearded Collies were submitted to
our laboratory by the dog’s owner or veterinarian. Addi-
sonian dogs (AD cases) included in this study were se-
lected based on a veterinary diagnosis of primary
hypoadrenocorticism that included an ACTH stimula-
tion test (serum cortisol levels < 55 nmol/L before and
after ACTH administration) and evidence of electrolyte
imbalance (sodium to potassium ratio < 27:1) and had no
other concurrent illnesses (diagnosed or suspected). The
AD cases had an average age of AD diagnosis of 50
months (range 5 to 120 months). Dogs included as
healthy controls were at least 10 years old (average 12.5
years), with no history of AD or other autoimmune dis-
eases (diagnosed or suspected). Samples were subjected
to DNA extraction as previously described [55], and
DNA aliquots quantified using a Nanodrop® spectropho-
tometer and stored at − 20 °C until further analysis.
Genome-wide association study
One hundred and forty-three DNA samples, consisting
of 59 AD cases (22 males, 37 females) and 84 controls
(34 males, 50 females), were genotyped at GeneSeek
(Lincoln, NE) using the Illumina CanineHD BeadChip
(San Diego, CA) containing 173,662 SNPs. Reference al-
leles and SNP locations were based on the CanFam3.1
reference genome; alleles differing from the reference al-
lele at any given location were referred to as alternate al-
leles. Individuals and SNPs with less than 95% call rates
as well as SNPs with minor allele frequency less than 1%
were removed from the dataset using PLINK version 1.9
[56]. Autosomal SNPs with a minor allele frequency
greater than 1% were then used to generate a genetic re-
lationship matrix for the remaining dogs using GCTA
[57]; closely related individuals were excluded from
GWAS analysis based on a relatedness cutoff of 0.3. Of
the 143 dogs that underwent GWA analyses, 36 (17 AD
cases, 19 controls) were removed from the analysis based
on a relatedness cutoff of 0.3, and four dogs (one AD
case and three controls) were excluded from analysis due
to poor genotyping. Association analyses using the 98,540
SNPs remaining after quality control was done on the 103
unrelated dogs (41 AD cases and 62 controls) using
PLINK version 1.9 [56] following exclusion of SNPs that
deviated from Hardy-Weinberg equilibrium among con-
trols (p > 0.0001) and/or with a minor allele frequency less
than 5%. The univariate linear mixed model approach im-
plemented by GEMMA [58] was also used to account for
any remaining population structure. As previously noted
[34], most of the SNPs used in a canine GWAS are in
linkage disequilibrium with multiple other SNPs, thus the
number of SNPs used for analysis does not accurately rep-
resent the number of independent tests. To avoid overcor-
recting for multiple testing, genome-wide significance was
established using a Bonferroni-corrected alpha value of
0.05 divided by the effective number of independent SNPs
as determined by GEC (Genetic type 1 error calculator)
[59]. Based on published studies addressing the genetics of
complex traits in dogs, a threshold for suggestive associ-
ation was set at p ≤ 0.00005 [34, 35].
Haplotype analysis
To narrow down regions of interest for candidate gene
exploration, haplotype analysis of the GWAS data was
done using Haploview version 4.2 [60] and 25,000 per-
mutations on the chromosomes containing SNPs with
suggestive and/or genome-wide significant association
with AD. Genes overlapping with haplotype blocks were
explored for potential involvement in AD development.
Genotyping of the four GWAS SNPs of interest on
additional dogs
Polymerase chain reaction (PCR) was used to genotype
significant and suggestive SNPs of interest (CFA11:
BICF2G630307993, CFA16: BICF2G630109748, CFA18:
BICF2P1230367 and CFA29: BICF2P977298) on additional
dogs selected to be minimally related to those used for
GWAS based on pedigree analysis, that is sharing no more
than one grandparent. Primers flanking each of the SNPs






GCAACC, CFA29-R: CCTGTGCTTGGATGTGATTG). A
standard 31 cycle PCR protocol was used with an annealing
temperature of 60 °C for the CFA11, CFA16 and CFA18
primer sets and 62 °C for the CFA29 primers. A 25 μL reac-
tion and Promega GoTaq® Flexi DNA Polymerase (Pro-
mega, WI, USA) were used. Amplicon size was confirmed
by running 6 μL of the PCR product on a 1% agarose gel.
Exosap-IT™ express (Thermo Fisher Scientific, Waltham,
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MA, USA) was used to purify the PCR products ac-
cording to the manufacturer’s recommendations, and
these were then sequenced by capillary electrophoresis
on an ABI 3730 DNA analyzer (Applied Biosystems,
Foster City, CA, USA). Sequences were read using
FinchTV v.1.4 (Geospiza, USA) and genotypes ob-
tained by aligning the sequences against the Can-
Fam3.1 reference sequence using CLC viewer v.7.8.1
(QIAGEN Bioinformatics, Denmark).
Statistical analysis
Odds ratio (OR) and two-tailed Fisher’s exact p-values
were calculated using a 2 × 2 contingency table in
VassarStats (http://vassarstats.net/odds2x2.html); OR
calculations were based on the number of AD cases
and healthy controls carrying a particular genotype
compared to the number of cases and controls not
carrying that genotype. Additionally, OR calculations
included genotypic pairwise comparisons (i.e. homozy-
gous alternate versus heterozygous; homozygous alter-
nate versus homozygous reference; and heterozygous
versus homozygous reference) to identify which geno-
types conferred risk for AD. Statistical significance
was set at p < 0.05.
Logistic regression was used to model the risk of
disease as a function of the observed genotypes at
each of the four SNPs of interest (CFA11:
BICF2G630307993, CFA16: BICF2G630109748,
CFA18: BICF2P1230367 and CFA29: BICF2P977298)
across the unrelated dogs. Disease probability was de-
fined by methods previously described [62]. Briefly,
the logit of disease probability was modeled as a
function of the SNP genotypes representing 3 classes
(e.g., AA, AG and GG with 2 degrees of freedom in
the analysis). Genotypic effects and predictions of dis-
ease risk were determined using the Bayesian statis-
tical package Stan [63] executed in R [64]. A series of
models were built using various combinations of the
potentially important SNPs and the model with the
best predictive accuracy for disease was identified
using the leave-one-out cross-validation process [65],
which calculates a statistic referred to as the leave-
one-out information criterion (looic). Similar to that
observed with the Akaike Information Criterion (AIC)
for frequentist methods, the model with the smallest
looic value is considered the best fit for predicting
disease status. Looic calculation was performed for
each of the models using the R package loo [66]. The
receiver operating characteristic curve, fitted with the
R package pROC [67], was then used to assess the
value of the models in disease prediction and define
the optimal discrimination threshold for assigning a
healthy or AD status to dogs based on each individ-
ual’s known SNP genotypes.
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Additional file 1: Figure 1. Logistic regression analysis for the four
SNPs of interest. Probability of AD associated with the 81 plausible 4-SNP
genotypic combinations based on known genotypes and phenotypes of
140 Bearded Collies (55 AD cases, 85 controls). Logistic regression calcu-
lates probabilities for genotypic combinations that are not included in
the data set, so one can still predict the disease risk for all 81 plausible
genotypes recognizing that the predictions in these “empty cells” is not
very precise and the confidence intervals surrounding the probability esti-
mates will be large. Based upon the observed data, probability estimates
in excess of 0.42 were associated with AD risk whereas genetic combina-
tions that had a probability below 0.42 were associated with reduced AD
risk. Thus, in this figure, 0.42 was set as the baseline zero value. Probability
estimates in excess of that figure are depicted above the line and those
lower are depicted as below the line. For example, the highest probability
calculated was 0.974, which would be represented as 0.55 above the
threshold value of 0.42.
Additional file 2: Table 1. Genotypes of the Bearded Collies analyzed
at the four SNPs of interest. Genotypes of the 140 Bearded Collies (55 AD
cases, 85 healthy controls) analyzed at each of the four SNPs of interest:
BICF2G630307993 on canine chromosome (CFA) 11, BICF2G630109748 on
CFA16, BICF2P1230367 on CFA18 and BICF2P977298 on CFA29.
Additional file 3: Table 2. Model assessment. Values for the leave-one-
out information criterion (looic) and standard error associated with each
of the predictive SNP models tested. The model with the smallest looic
value is considered the best, most parsimonious, fit.
Additional file 4: Table 3. Haplotype blocks associated with Addison’s
disease in Bearded Collies. Haplotype blocks associated with Addison’s
disease on canine chromosomes 11, 16 and 18 in 103 unrelated Bearded
Collies (41 cases, 62 controls). Locations represent the position of the first
and last single nucleotide polymorphism (SNP) in each block and are
based on the CanFam3.1 reference genome.
Abbreviations
AD: Addison’s disease; CFA: Canine chromosome;; GWAS: Genome wide
association study; OMIA: Online Mendelian inheritance in animals;
PWD: Portuguese Water Dog; NSDTR: Nova Scotia Duck Tolling Retriever;
MHC: Major histocompatibility complex; CTLA4: Cytotoxic T-lymphocyte-
associated protein 4; PTPN22: Protein tyrosine-phosphatase non-receptor
type 22; CIITA: MHC class II transactivator; AIRE: Autoimmune regulator;
SNP: Single nucleotide polymorphism; OSBPL9: Oxysterol binding protein like
9 gene; DLA: Dog leukocyte antigen; COL4A4: Collagen type IV alpha 4
chain; STXBP5: Syntaxin-binding protein 5; GC: Vitamin D binding protein
group-specific component; SP110: SP110 nuclear body protein; OR: Odds
ratio; CI: Confidence interval; LOOIC: Leave-one-out criterion; TLR4: The toll-
like receptor 4; ZMAT4: Zinc finger matrin-type 4; FGFR1: Fibroblast growth
factor receptor 1; LETM2: Leucine zipper and EF-hand containing transmem-
brane protein 2; EIF4EBP1: Eukaryotic translation initiation factor 4E binding
protein 1; ADRB3: Adrenoreceptor beta 3; GOT1L1: Glutamic-oxaloacetic
transaminase 1 like 1; RAB11FIP1: RAB11 family interacting protein 1;
BRF2: BRF2 RNA polymerase III transcription initiation factor subunit;
RNA: Ribonucleic acid; RELN: Reelin; SLC26A5: Solute carrier family 26
member 5; LRRC4C: Leucine rich repeat containing 4C; NGL-1: Netrin-G1
ligand; SLE: Systemic lupus erythematosus; RA: Rheumatoid arthritis;
DoGA: The Dog Genome Annotation Project; OMIM: Online Mendelian
inheritance in man; lncRNA: Long noncoding ribonucleic acid; TNFS15: TNF
superfamily member 15; TNFSF8: TNF superfamily member 8; TCR: T-cell
receptor; ADRB3: Beta-3 adrenergic receptor; IDO2: Indoleamine 2,3-
dioxygenase 2; IDO1: Indoleamine 2,3-dioxygenase 1; STAR: Steroidogenic
acute regulatory protein; ACTH: Adrenocorticotropic hormone;
DNA: Deoxyribonucleic acid; PCR: Polymerase chain reaction; AIC: Akaike
information criterion
Acknowledgements
The authors would like to gratefully acknowledge the infrastructure support
of the Department of Animal Science, College of Agricultural and
Gershony et al. BMC Genomics          (2020) 21:833 Page 11 of 13
Environmental Sciences, and the California Agricultural Experiment Station of
the University of California, Davis. The authors would also like to thank Kaisu
Hiltunen for technical help and Elsa Sell and Linda Aronson for their
invaluable help in recruiting Bearded Collie samples, as well as all the owners
who have actively participated in our research projects, and every dog that
contributed to the study.
Authors’ contributions
LCG and AMO conceived and designed the study with input from JMB; LCG
performed laboratory and data analyses; TRF did all logistic regression analyses
and interpretation; funding was obtained by AMO and HL; resources were
obtained by AMO, HL and MKH. The original draft was written by LCG and
AMO and subsequently reviewed and edited by LCG, AMO, TRF, JMB, HL and
MKH. The authors have read and approved the manuscript.
Funding
This study was funded by the American Kennel Club Canine Health Foundation
(#02488, #02187-MOU, and #1236-A) and The Bearded Collie Foundation for
Health (BeaCon). The authors would also like to thank the Academy of Finland,
Helsinki Institute of Life Science and Jane and Aatos Erkko Foundation, the
Brazilian National Council for Scientific and Technological Development (CNPq)
and the Ann T. Bowling Fellowship for financial support. The Bearded Collie
Foundation for Health (BeaCon) contributed with sample recruitment. Funding
agencies were not involved in study design, sample collection, data analysis
and interpretation or writing of the manuscript.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article and its supplementary information files.
Ethics approval and consent to participate
The study followed all applicable guidelines for the care and use of animals,
and all procedures were in accordance with the ethical standards of the
University of California, Davis (IACUC #20402) and University of Helsinki,
Finland (permit ESAVI/6054/04.10.03/ 2012). Written informed consent was




The authors declare that they have no conflicts of interest.
Author details
1Department of Animal Science, University of California-Davis, Davis, CA
95616, USA. 2Brazilian National Council for Scientific and Technological
Development (CNPq) fellow, Brasilia, DF 71605, Brazil. 3Department of
Medical and Clinical Genetics, and Department of Veterinary Biosciences,
University of Helsinki, 00014 Helsinki, Finland; Folkhälsan Research Center,
Helsinki 00290, Finland.
Received: 14 May 2020 Accepted: 18 November 2020
References
1. Oberbauer A, Bell J, Belanger J, Famula T. Genetic evaluation of Addison's
disease in the Portuguese water dog. BMC Vet Res. 2006;2(1):15.
2. Boag AM, Catchpole B. A review of the genetics of Hypoadrenocorticism.
Top Companion Anim Med. 2014;29(4):96–101.
3. Bellumori TP, Famula TR, Bannasch DL, Belanger JM, Oberbauer AM.
Prevalence of inherited disorders among mixed-breed and purebred dogs:
27,254 cases (1995-2010). J Am Vet Med Assoc. 2013;242(11):1549–55.
4. Decôme M, Blais M-C. Prevalence and clinical features of
hypoadrenocorticism in great Pyrenees dogs in a referred population: 11
cases. Can Vet J= La revue veterinaire canadienne. 2017;58(10):1093–9.
5. Hanson JM, Tengvall K, Bonnett BN, Hedhammar Å. Naturally occurring
adrenocortical insufficiency – an epidemiological study based on a
Swedish-insured dog population of 525,028 dogs. J Vet Intern Med. 2016;
30(1):76–84.
6. Wiles BM, Llewellyn-Zaidi AM, Evans KM, O'Neill DG, Lewis TW. Large-scale
survey to estimate the prevalence of disorders for 192 kennel Club
registered breeds. Canine Genet Epidemiol. 2017;4:8.
7. Klein SC, Peterson ME. Canine hypoadrenocorticism: part I, vol. 51; 2010.
8. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet.
2014;383(9935):2152–67.
9. Massey J, Boag A, Short AD, Scholey RA, Henthorn PS, Littman MP, et al.
MHC class II association study in eight breeds of dog with
hypoadrenocorticism. Immunogenetics. 2013;65(4):291–7.
10. Short AD, Boag A, Catchpole B, Kennedy LJ, Massey J, Rothwell S, et al. A
candidate gene analysis of canine Hypoadrenocorticism in 3 dog breeds. J
Hered. 2013;104(6):807–20.
11. Burkitt JM. Chapter 76 - Hypoadrenocorticism. In: Silverstein DC, Hopper K, editors.
Small animal critical care medicine. Saint Louis: W.B. Saunders; 2009. p. 321–4.
12. Van Lanen K, Sande A. Canine Hypoadrenocorticism: pathogenesis,
diagnosis, and treatment. Top Companion Anim Med. 2014;29(4):88–95.
13. Hughes AM, Nelson RW, Famula TR, Bannasch DL. Clinical features and
heritability of hypoadrenocorticism in Nova Scotia duck tolling retrievers: 25
cases (1994-2006). J Am Vet Med Assoc. 2007;231(3):407–12.
14. Chase K, Sargan D, Miller K, Ostrander EA, Lark KG. Understanding the
genetics of autoimmune disease: two loci that regulate late onset Addison's
disease in Portuguese water dogs. Int J Immunogenet. 2006;33(3):179–84.
15. Famula TR, Belanger JM, Oberbauer AM. Heritability and complex
segregation analysis of hypoadrenocorticism in the standard poodle. J Small
Anim Pract. 2003;44(1):8–12.
16. Oberbauer AM, Benemann KS, Belanger JM, Wagner DR, Ward JH, Famula
TR. Inheritance of hypoadrenocorticism in bearded collies. Am J Vet Res.
2002;63(5):643–7.
17. Peterson ME, Kintzer PP, Kass PH. Pretreatment clinical and laboratory
findings in dogs with hypoadrenocorticism: 225 cases (1979-1993). J Am Vet
Med Assoc. 1996;208(1):85–91.
18. Brown E, Young A, Wolf Z, Wade CM, Hughes A, Foreman O, et al. Juvenile
Hypoadrenocorticism in the Nova Scotia duck tolling retriever: a recessive
monogenic autoimmune disease. Denver: American College of Veterinary
Internal Medicine Forum: 2016; 2016. p. 1407–519. Journal of Veterinary
Internal Medicine.
19. Mitchell AL, Pearce SHS. Autoimmune Addison disease: pathophysiology
and genetic complexity. Nat Rev Endocrinol. 2012;8(5):306–16.
20. Boag AM, Christie MR, McLaughlin KA, Syme HM, Graham P, Catchpole B.
Autoantibodies against cytochrome P450 side-chain cleavage enzyme in
dogs (Canis lupus familiaris) affected with Hypoadrenocorticism (Addison’s
disease). PLoS One. 2015;10(11):e0143458.
21. Soderbergh A, Winqvist O, Norheim I, Rorsman F, Husebye ES, Dolva O,
et al. Adrenal autoantibodies and organ-specific autoimmunity in patients
with Addison's disease. Clin Endocrinol (Oxf). 1996;45(4):453–60.
22. Friedenberg SG, Brown DL, Meurs KM, Law JM. Lymphocyte subsets in the
adrenal glands of dogs with primary Hypoadrenocorticism. Vet Pathol. 2018;
55(1):177–81.
23. Boag AM, McLaughlin K, Christie M, Graham P, Syme H, Catchpole B.
Analysis of P450 side-chain cleavage enzyme autoantibodies in dogs
affected with hypoadrenocorticism. (2014 ACVIM forum research abstracts
program). J Vet Intern Med. 2014;28(3):976–1134.
24. Betterle C, Morlin L. Autoimmune Addison's disease. Endocr Dev. 2011;20:
161–72.
25. Løvås K, Husebye ES. Addison's disease. Lancet. 2005;365(9476):2058–61.
26. Skinningsrud B, Husebye ES, Pearce SH, McDonald DO, Brandal K, Wolff
AB, et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated
with primary adrenal insufficiency. J Clin Endocrinol Metab. 2008;93(9):
3310–7.
27. Friedenberg SG, Lunn KF, Meurs KM. Evaluation of the genetic basis of primary
hypoadrenocorticism in standard poodles using SNP array genotyping and
whole-genome sequencing. Mamm Genome. 2017;28(1–2):56–65.
28. Boag AM, Short A, Kennedy LJ, Syme H, Graham PA, Catchpole B.
Polymorphisms in the CTLA4 promoter sequence are associated with
canine hypoadrenocorticism. Canine Med Genet. 2020;7(1):2.
29. Gershony LC, Belanger JM, Short AD, Le M, Hytönen MK, Lohi H, et al. DLA
class II risk haplotypes for autoimmune diseases in the bearded collie offer
insight to autoimmunity signatures across dog breeds. Canine Genet
Epidemiol. 2019;6(1):2.
30. Hughes AM, Jokinen P, Bannasch DL, Lohi H, Oberbauer AM.
Association of a dog leukocyte antigen class II haplotype with
Gershony et al. BMC Genomics          (2020) 21:833 Page 12 of 13
hypoadrenocorticism in Nova Scotia duck tolling retrievers. Tissue
Antigens. 2010;75(6):684–90.
31. Treeful A, Rendahl A, Friedenberg S. Sex-specific DLA class II haplotypes are
associated with primary hypoadrenocorticism in standard poodle dogs.
J Immunol. 2019;202(1 Supplement):73.79.
32. Short AD, Catchpole B, Boag AM, Kennedy LJ, Massey J, Rothwell S,
Henthorn PS, Littman MP, Husebye E, Ollier B. Putative candidate genes for
canine hypoadrenocorticism (Addison's disease) in multiple dog breeds
Veterinary Record. 2014;175:430.
33. Bearded Collie Foundation for Health. BeaCon open health registry report; 2019.
34. Karlsson EK, Sigurdsson S, Ivansson E, Thomas R, Elvers I, Wright J, et al.
Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma,
including regulatory variants near CDKN2A/B. Genome Biol. 2013;14(12):
R132.
35. Baker LA, Kirkpatrick B, Rosa GJM, Gianola D, Valente B, Sumner JP, et al.
Genome-wide association analysis in dogs implicates 99 loci as risk variants
for anterior cruciate ligament rupture. PLoS One. 2017;12(4):e0173810.
36. Hughes AM, Bannasch DL, Kellett K, Oberbauer AM. Examination of
candidate genes for hypoadrenocorticism in Nova Scotia duck tolling
retrievers. Vet J. 2011;187(2):212–6.
37. Lin JC, Ho W-H, Gurney A, Rosenthal A. The netrin-G1 ligand NGL-1 promotes
the outgrowth of thalamocortical axons. Nat Neurosci. 2003;6(12):1270–6.
38. Gao Y, Li S, Zhang Z, Yu X, Zheng J. The role of long non-coding RNAs in
the pathogenesis of RA, SLE, and SS. Front Med (Lausanne). 2018;5:193.
39. Fu Y, Tessneer KL, Li C, Gaffney PM. From association to mechanism in
complex disease genetics: the role of the 3D genome. Arthritis Res Ther.
2018;20(1):216.
40. Schaechinger TJ, Oliver D. Nonmammalian orthologs of prestin (SLC26A5)
are electrogenic divalent/chloride anion exchangers. Proc Natl Acad Sci.
2007;104(18):7693–8.
41. Tissir F, Goffinet AM. Reelin and brain development. Nat Rev Neurosci. 2003;
4(6):496–505.
42. Greenjohnson JM, Zalcman S, Vriend CY, Nance DM, Greenberg AH.
Suppressed T cell and macrophage function in the "Reeler" (rl/rl) mutant, a
murine strain with elevated cerebellar norepinephrine concentration. Brain
Behav Immun. 1995;9(1):47–60.
43. Mohammad Hosseini A, Majidi J, Baradaran B, Yousefi M. Toll-like receptors
in the pathogenesis of autoimmune diseases. Adv Pharm Bull. 2015;5(Suppl
1):605–14.
44. Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in autoimmune diseases: a
comprehensive review. Clin Rev Allergy Immunol. 2014;47(2):136–47.
45. Bayry J. TL1A in the inflammatory network in autoimmune diseases. Nat Rev
Rheumatol. 2010;6(2):67–8.
46. Aiba, Yoshihiro, and Minoru Nakamura. The role of TL1A and DR3 in
autoimmune and inflammatory diseases. Mediators Inflamm. 2013;
2013(258164):9. https://doi.org/10.1155/2013/258164.
47. Zhang M, Liu S, Xu J, Lv S, Fan Y, Zhang Y, Zhang Y, Wu Y, Su Y, Yu H, Song
S, He J, Li H. TNFSF15 polymorphisms are associated with graves' disease
and graves' ophthalmopathy in a Han Chinese population. Curr Eye Res.
2020;45(7):888–95. https://doi.org/10.1080/02713683.2019.1705494. Epub
2019 Dec 27.
48. Mackay F, Kalled SL. TNF ligands and receptors in autoimmunity: an update.
Curr Opin Immunol. 2002;14(6):783–90.
49. Patel RK, Mohan C. PI3K/AKT signaling and systemic autoimmunity.
Immunol Res. 2005;31(1):47–55.
50. Merlo LMF, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-
Nayak L. IDO2 modulates T cell–dependent autoimmune responses through
a B cell–intrinsic mechanism. J Immunol. 2016;196(11):4487.
51. Merlo LMF, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, et al.
IDO2 is a critical mediator of autoantibody production and inflammatory
pathogenesis in a mouse model of autoimmune arthritis. J Immunol. 2014;
192(5):2082.
52. King SR, Bhangoo A, Stocco DM. Functional and physiological
consequences of StAR deficiency: role in lipoid congenital adrenal
hyperplasia. Pediatr Adrenal Dis. 2011;20Karger Publishers:47–53.
53. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to
autoimmunity. Nat Immunol. 2017;18:716.
54. Bell JS. AKC Bearded Collie Stud Book & Genetic Diversity Analysis. In., vol.
2017http://www.beaconforhealth.org/Final_Stud_Book_
Analysis%20with%20edit%20restrictions.pdf; 2017.
55. Rincon G, Tengvall K, Belanger JM, Lagoutte L, Medrano JF, Andre C, et al.
Comparison of buccal and blood-derived canine DNA, either native or
whole genome amplified, for array-based genome-wide association studies.
BMC Res Notes. 2011;4:226.
56. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-
generation PLINK: rising to the challenge of larger and richer datasets.
GigaScience. 2015;4(1).
57. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide
complex trait analysis. Am J Hum Genet. 2011;88(1):76–82.
58. Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for
association studies. Nat Genet. 2012;44(7):821–4.
59. Li MX, Yeung JM, Cherny SS, Sham PC. Evaluating the effective numbers of
independent tests and significant p-value thresholds in commercial
genotyping arrays and public imputation reference datasets. Hum Genet.
2012;131(5):747–56.
60. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics. 2005;21(2):263–5.
61. Koressaar T, Remm M. Enhancements and modifications of primer design
program Primer3. Bioinformatics. 2007;23(10):1289–91.
62. Belanger JM, Famula TR, Gershony LC, Palij MK, Oberbauer AM. Genome-
wide association analysis of idiopathic epilepsy in the Belgian shepherd.
Canine Med Genet. 2020;7(1):12.
63. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M,
et al. Stan: a probabilistic programming language. J Stat Softw. 2017;76(1).
64. R Core Team. R: a language and environment for statistical computing. Vienna:
R Foundation for Statistical Computing; 2020. https://www.R-project.org/.
65. Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using
leave-one-out cross-validation and WAIC. Stat Comput. 2017;27(5):1413–32.
66. Vehtari A, Gabry J, Magnusson M, Yao Y, Bürkner P, Paananen T, Gelman A.
loo: Efficient leave-one-out cross-validation and WAIC for Bayesian models.
R package version 2.3.1. 2020. https://mc-stan.org/loo.
67. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an
open-source package for R and S+ to analyze and compare ROC curves.
BMC Bioinformatics. 2011;12(1):77.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Gershony et al. BMC Genomics          (2020) 21:833 Page 13 of 13
